MBC testifies at DPH Regulations Hearing
Proposed pharmaceutical and medical device sales & marketing regulations will jeopardize the momentum of the growing life sciences industry in Massachusetts, MBC President & CEO Robert Coughlin testified at a hearing today.
Coughlin joined representatives from a number of MBC companies to express concern over regulations proposed by the Department of Public Health to regulate contact between pharmaceutical and medical device companies and health care practitioners.
"While we as an industry support the concept of transparency between physicians and manufacturers' sales representatives, we continue to have concerns about the impact these regulations may have on life science companies in the Commonwealth," Coughlin said.
To read the testimony in it's entirety,click here .
To read the draft regulations, click here.
The hearing came just one day after a MBC Law & Policy Committee meeting focused on the impact of the proposed regulations. The session's panelists provided insight into the proposed regulations from the legal, industry, and regulatory perspectives.
The panel presentations are available for download:
Presentation by Pat Cerundolo, Partner, Foley Hoag LLP
Presentation by Melissa Lopes, Deputy General Counsel, Massachusetts Department of Public Health
Presentation by Roger Louis, Senior Vice President, Healthcare and Regulatory Counsel, & Chief Compliance Officer, Genzyme